AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel miniprotein therapeutics, today announced the appointment of Dr. Philip E. Brandish, PhD as Chief Development Officer (CDO). Dr. Brandish brings vast leadership experience in the life sciences sector, with a proven track record of discovery and development of novel therapeutics, leading program teams from target validation and candidate selection through IND and into clinical proof-of-concept.

“Phil is a crucial addition to our leadership team, bringing extensive experience developing drugs, driving collaborations and leading high-performing teams,” said Dr. Chris Bahl, President, CEO and Founder of AI Proteins. “Phil joins us at an exciting time, as our platform is churning out lead molecules that address highly-demanding therapeutic criteria at breakneck speed. Phil will lead our rigorous target selection and prioritization process in addition to our development efforts.”

Dr. Brandish joins AI Proteins from Bicycle Therapeutics where he most recently served as Senior Vice President with responsibility for the internal preclinical pipeline and US-based research scientists. Prior to Bicycle, Dr. Brandish was a veteran leader at Merck & Co, Inc. where he oversaw early development of pre-clinical and clinical-stage Oncology programs.

“I am thrilled and privileged to be joining forces with Chris and the extraordinary team of scientists at AI Proteins,” said Dr. Brandish. “The AI-based miniprotein discovery platform that they have created and reduced to practice presents an unparalleled opportunity. That is, to create impactful new therapeutics that precisely meet the design goals dictated by the disease biology and by what patients need.”

About AI Proteins

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for a variety of therapeutic applications. Partnered with leading global biopharmaceutical companies the Company continues to pursue collaborations across a wide variety of therapeutic areas in addition to advancing its internal pipeline. The company’s technology enables the development of inexpensive, durable, highly specific proteins with differentiated and enhanced therapeutic properties and with the potential for multiple routes of delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. For more information please visit aiproteins.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212546420/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.